IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease
01 août 2023 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Aug. 01, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing...
IntelGenx Provides Update on Research Collaboration Evaluating Montelukast VersaFilm® for the Treatment of Parkinson’s Disease
25 juil. 2023 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 25, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced the execution of a Research Grant Agreement with...
IntelGenx Announces a Change to its Board of Directors
21 juil. 2023 16h30 HE
|
IntelGenx Technologies Corp.
SAINT-LAURENT, Quebec, July 21, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces the resignation of Mr. J. Bernard (Bernie)...
IntelGenx Announces Voting Results on Election of Directors
06 juil. 2023 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, July 06, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Company” or “IntelGenx”) announces that, at the annual meeting of shareholders of...
IntelGenx Unveils Short-Term Commercial Objectives
31 mai 2023 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 31, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it is executing on a plan focussed on near-term...
IntelGenx Receives Amended DEL License to Conduct Third-Party Testing
17 mai 2023 08h00 HE
|
IntelGenx Technologies Corp.
- Provides opportunity to address market gap, catering to growing industry demand for reliable and efficient testing services - SAINT LAURENT, Quebec, May 17, 2023 (GLOBE NEWSWIRE) -- IntelGenx...
IntelGenx Reports First Quarter 2023 Financial Results
11 mai 2023 16h05 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 11, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the first quarter...
IntelGenx to Report First Quarter 2023 Financial Results on May 11, 2023 – Conference Call to Follow
04 mai 2023 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, May 04, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that it will release its...
IntelGenx Extends Period to Exercise Certain Warrants
27 avr. 2023 16h30 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 27, 2023 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) announces that it has received conditional approval...
IntelGenx Announces Receipt of Complete Response Letter from the FDA for Xiromed-Partnered Buprenorphine Buccal Film
27 avr. 2023 08h00 HE
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, April 27, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that its co-developer, Chemo Research SL, through its...